|
|
|
| Helpful Biosafety Testing Innovations: Where and When You Need Them | Manufacturers of monoclonal antibodies (mAbs) are continually pushing the boundaries to improve the efficiency, efficacy, and accessibility of their production. Learn how advanced biosafety testing techniques, including next-generation sequencing (NGS) and the Blazar® platform, are revolutionizing production efficiency and safety. Curious about how these innovations are reshaping the industry? Check out the full article! |
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | According to Global Data, the total deal value of U.S. licensing of innovator drug candidates from Chinese biopharma companies has surged since 2020. This is an area way upstream of the current tariff focus on manufacturing. But how this R&D trend and those tariffs play out will impact your U.S.-based CDMOs. | |
|
|
|
|
|
| 3 Key Trends Shaping The CDMO Industry | Article | By Cory Lewis, INCOG BioPharma Services | Stay up to date on the future of CDMOs. Read about key trends such as adopting a customer-centric mindset, agile manufacturing, and embracing digitalization. |
|
|
|
|
|
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|
